|
WO2020243650A1
|
|
Deuterated analogs of d-serine and uses thereof
|
|
WO2020243638A1
|
|
Methods of treatment with deuterated analogs of d-serine
|
|
WO2020206367A1
|
|
Processes for the preparation of deuterated d-serine
|
|
WO2020163653A1
|
|
Process for preparing enantiomerically enriched jak inhibitors
|
|
WO2020132461A1
|
|
Deuterated forms and derivatives of volinanserin
|
|
WO2020092604A1
|
|
Deuterated pitolisant
|
|
WO2019183564A1
|
|
DEUTERATED ANALOGS OF D-β-HYDROXYBUTYRIC ACID AND USES THEREOF
|
|
WO2019104179A1
|
|
Deuterated analogs of d-serine and uses thereof
|
|
JP2018188474A
|
|
Deuterated cftr potentiator
|
|
JP2018172421A
|
|
Deuteration derivatives of ruxolitinib
|
|
WO2018106916A1
|
|
Deuterated quinoxaline compounds
|
|
WO2018039521A1
|
|
Deuterated cenicriviroc
|
|
WO2018023009A1
|
|
Deuterated lurasidone
|
|
WO2018013625A1
|
|
Deuterated miconazole
|
|
WO2018013686A1
|
|
Deuterated idalopirdine
|
|
US2019225607A1
|
|
Deuterated Venetoclax
|
|
WO2018005328A1
|
|
Deuterated bictegravir
|
|
WO2017210261A1
|
|
Deuterated fevipiprant
|
|
WO2017201043A1
|
|
Combination therapy for treating cancer
|
|
CN109069493A
|
|
With deuterated JAK inhibitor for treating depilation obstacle
|
